Table 5.
ICERs of scenario analyses from the Chinese private payer perspective (CNY per QALY gained)
| PEACE | BERSON | SuValue® LDL-C ≥ 100 mg/dl |
SuValue® LDL-C ≥ 70 mg/dl |
|||||
|---|---|---|---|---|---|---|---|---|
| Evo 140mgQ2W | Evo 420mgQM | Evo 140mgQ2W | Evo 420mgQM | Evo 140mgQ2W | Evo 420mgQM | Evo 140mgQ2W | Evo 420mgQM | |
| Time horizon | ||||||||
| 5 years | 538578.65 | 840636.79 | 481061.72 | 873164.78 | 174043.04 | 360901.94 | 301236.99 | 535743.77 |
| 10 years | 264847.73 | 420839.28 | 225087.72 | 422267.59 | 75562.59 | 175411.94 | 142255.13 | 266727.23 |
| 15 years | 173410.07 | 278957.63 | 139891.58 | 268955.17 | 45586.22 | 114800.18 | 91036.01 | 176928.74 |
| 20 years | 135696.37 | 220129.52 | 101220.39 | 198558.46 | 33040.08 | 88467.34 | 68849.69 | 137449.49 |
| 30 years | 118511.82 | 194227.70 | 75503.67 | 152378.28 | 24439.97 | 71303.95 | 53946.33 | 111850.08 |
| 35 years | 117217.93 | 192854.18 | 72506.95 | 147936.29 | NA | NA | NA | NA |
| Starting age | ||||||||
| 65-year | 108771.20 | 177305.36 | 64624.43 | 129223.90 | NA | NA | NA | NA |
| 70-year | 93050.81 | 152702.01 | 49543.94 | 101051.16 | 26725.74 | 74512.59 | 56998.67 | 116023.46 |
| 75-year | 76221.16 | 127484.02 | 36443.19 | 77920.22 | 20824.50 | 58466.14 | 43803.33 | 90095.23 |
| Discount rate | ||||||||
| 3% | 108174.04 | 177445.07 | 72565.94 | 146128.62 | 23150.27 | 67577.18 | 51123.46 | 105957.15 |
| 6% | 129263.01 | 210373.48 | 88758.57 | 176048.14 | 29692.79 | 81585.10 | 62878.15 | 127051.85 |
| Annual Cost of Stains (CNY) a | ||||||||
| 118.86 | 120022.58 | 197045.16 | 81914.54 | 164396.45 | 25227.33 | 74536.00 | 56608.02 | 117548.43 |
| 5470.28 | 123863.78 | 200886.36 | 83735.51 | 166224.98 | 29521.56 | 78830.23 | 60907.22 | 121847.64 |
| Costs of CV-related death b | ||||||||
| Death due to stroke 1 | 100522.74 | 177545.32 | 61045.06 | 143405.39 | 2979.10 | 52287.76 | 34099.45 | 95039.86 |
| Death due to stroke 2 | 114482.41 | 191504.99 | 75468.74 | 157909.73 | 18935.65 | 68244.32 | 50234.53 | 111174.94 |
| Death due to MI 1 | 94656.25 | 171678.83 | 55830.30 | 137955.69 | Dominance | 41690.59 | 24793.53 | 85733.94 |
| Death due to MI 2 | 69467.93 | 146490.51 | 24696.42 | 106532.67 | Dominance | 4528.46 | Dominance | 49006.85 |
| Utility b | ||||||||
| Higher utility | 130475.81 | 218258.57 | 90208.50 | 180284.52 | 30171.23 | 84421.29 | 64950.45 | 132258.00 |
| Lower utility | 105182.33 | 175947.90 | 78362.40 | 155803.00 | 25665.76 | 71814.68 | 54882.83 | 111757.38 |
| UK- utility | 119895.54 | 200560.01 | 88272.39 | 174919.55 | 28466.22 | 79650.55 | 60874.92 | 123959.02 |
| Hospital classification c | ||||||||
| County hospitals | 139220.80 | 216243.38 | 102079.64 | 184879.97 | 54709.26 | 104017.93 | 85032.51 | 145972.92 |
| County-level municipal hospitals | 134508.03 | 211530.61 | 96579.00 | 179335.09 | 46786.37 | 96095.03 | 77442.66 | 138383.07 |
| Prefecture-level municipal hospitals | 120332.05 | 197354.62 | 81196.28 | 163645.82 | 24721.08 | 74029.74 | 56226.15 | 117166.56 |
| Provincial hospitals | 118859.87 | 195882.45 | 78581.27 | 160974.85 | 20756.61 | 70065.28 | 52612.97 | 113553.38 |
| Hospitals directly under the Health Commission | 113799.45 | 190822.02 | 73017.46 | 155300.28 | 12840.81 | 62149.47 | 44959.21 | 105899.62 |
CNY, Chinese Yuan; Dominance, ICERs, incremental cost-effectiveness ratio; Lower cost, higher utility; LDL-C, low-density lipoprotein cholesterol; MI, myocardial infarction; NA, not applicable
italic text: ICERs below CNY 85698 (US$12741); bold text: ICERs above CNY 257094 (US$38224).
a: the maximum and minimum annual cost of statins, more detailed parameters are shown in Supplementary Tables S4
b: CV-related mortality costs used in other CEA studies and beyond the scope of sensitivity analysis, more detailed parameters are shown in Supplementary Tables S5
c: Utility used in other CEA studies and beyond the scope of sensitivity analysis, more detailed parameters are shown in Supplementary Tables S6